In the following video, Motley Fool health care analyst Brenton Flynn discusses Bausch & Lomb and the scuttlebutt surrounding a potential acquirer. He talks about Abbott Labs (ABT 1.96%), Johnson & Johnson (JNJ +0.74%), Sanofi (SNY 0.52%), Pfizer (PFE +0.77%), and Merck (MRK +1.50%), and just how realistic this purchase would be for each. He also gives his bet on which company, in the end, may be the buyer.